HOME >> BIOLOGY >> NEWS
Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps

Investigational Drug Halts New Polyp Formation; Appears Well-Tolerated For Extended Use

HORSHAM, PA (May 20, 1998) -- Cell Pathways, Inc. today announced results from an open-label extension study of the company's lead investigational compound, FGN-1--(exisulind), in patients with Familial Adenomatous Polyposis (FAP; also known as Adenomatous Polyposis Coli, APC). Eighteen patients continuing on FGN-1 for as long as 18 months following the completion of a six month Phase I/II dose-ranging, safety and efficacy trial tolerated drug treatment well. The progressive increase in precancerous polyps that normally occurs in this patient population appeared to be arrested by the treatment. In addition, existing polyps in the FGN-1 treated patients appeared to decrease in size or remain stable over time.

The extension study results will be presented today at the American Gastroenterological Association meeting in New Orleans, Louisiana by clinical investigator, Rosalind van Stolk, M.D. of the Cleveland Clinic Foundation.

"FAP patients have historically experienced, on average, a significant increase in the number of precancerous polyps that develop in their rectum over a 12 month period," said Dr. van Stolk. "In contrast, we observed that new polyp formation halted in all patients receiving effective doses of FGN-1 for periods of 12 to 24 months, and in 16/18 patients, small polyps (6 mm or less) tended to regress in size while larger polyps remained stable."

"We are very encouraged by these results, which show a strong trend that supports FGN-1's ability to prevent the normal progression of disease in patients with FAP," said Rifat Pamukcu, M.D., chief scientific officer and senior vice president of research and development at Cell Pathways. "Left untreated, FAP patients invariably develop colon cancer." He noted that a randomized, placebo-controlled Phase III trial of FGN-1 i
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
20-May-1998


Page: 1 2 3

Related biology news :

1. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
2. Pathways of emotion from cortex to peripheral organs
3. Cell Pathways CP461 demonstrates multiple anti-cancer activities
4. Cell Pathways scientists describe mechanism by which SAANDS compounds trigger programmed death in cancerous and precancerous cells
5. Pitt Researchers Find Way To Block Cellular Growth Pathways And Inhibit Tumor Growth
6. Discovery Of Genetic Pathways May Provide New Ways To Combat Candida Infections
7. Reports of "weird life" almost stranger than fiction
8. Reports from special environmental health issue explore links to autoimmune diseases - diabetes, lupus, multiple scleroris and arthritis
9. Osiris Therapeutics Reports Key Findings in SCIENCE Verifying Existence of Adult Stem Cells
10. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
11. New England Journal Of Medicine Reports Calcium Supplements Help Prevent Polyp Recurrence; DMS Led Study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/16/2019)... , ... April 16, 2019 , ... ... featured speakers for two signature events: The 2019 ISPE Biopharmaceutical Manufacturing Conference ... on 20–21 June. Taking place in one of the most influential bio hubs, ...
(Date:4/12/2019)... ... April 12, 2019 , ... Gnubiotics ... complex microbiota accessible carbohydrates (MACs) as specialty ingredients for the global animal and ... Register and commercial launch of its first-in class microbiome modulating prebiotic GNU100, for ...
(Date:4/5/2019)... ... April 04, 2019 , ... PI’s ... providing 0.05 microns and 0.005 microns resolution, respectively. The new design allows for ... available, from fast DC-servo motors with linear encoders and low-friction ball-screws to simple ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... ... April 08, 2019 , ... CallTower, a ... the launch of their app integration solution, CT Cloud Unite. CT Cloud ... while using CT Cloud Voice and Skype for Business solutions. This robust integration ...
(Date:3/29/2019)... MOUNTAIN VIEW, Calif. (PRWEB) , ... March 28, ... ... the achievement of development and testing milestones, CARB-X has proceeded with a second ... will receive up to $1.7 million, which is on top of the $1.7 ...
(Date:3/23/2019)... ... March 22, 2019 , ... Tosoh ... Light Scattering (MALS) detector , offering a revolutionary approach for the measurement of ... and biopolymers. A novel optical design, a unique cell-block assembly, and a new ...
(Date:3/19/2019)... ... ... will review strategies for data management in modular and adaptive clinical trials. , Participants will:, ... 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... reducing risk and impact on trial success, trial teams, and trial execution , ...
Breaking Biology Technology:
Cached News: